Autor: |
Zhong-Guo, Fan, Nai-Liang, Tian, Sheng-Hu, He, Gen-Shan, Ma |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
Journal of clinical pharmacy and therapeuticsREFERENCES. 47(7) |
ISSN: |
1365-2710 |
Popis: |
It is well known that high in-stent thrombotic risk due to the superimposition of a platelet-rich thrombus was considered as the main origin of major adverse cardiac events after stent implantation. The clinical management of antiplatelet therapy strategy after percutaneous coronary intervention (PCI) remains controversial. This study is sought to explore the efficacy and safety of a maintained P2YMedline, Google Scholar, Web of Science, and the Cochrane Controlled Trials Registry were searched online for retrieving eligible citations. A composite of all-cause death, myocardial infarction (MI) and stroke was defined as major adverse cardio- and cerebro-vascular events (MACCE), which is analysed as the primary efficacy endpoint. The risk of bleeding events was chosen as safety endpoint.Five randomized clinical trials (RCT) with 32,143 patients were finally analysed. A maintained P2YA maintained P2Y |
Databáze: |
OpenAIRE |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|